Fortitude Family Office’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.05K Buy
348
+63
+22% +$899 ﹤0.01% 1182
2026
Q1
$4.79K Hold
285
– – ﹤0.01% 930
2025
Q4
$4.57K Hold
285
– – ﹤0.01% 844
2025
Q3
$3.52K Sell
285
-92
-24% -$1.08K ﹤0.01% 956
2025
Q2
$4.34K Buy
377
+350
+1,296% +$4.15K ﹤0.01% 837
2025
Q1
$405 Hold
27
– – ﹤0.01% 1089
2024
Q4
$467 Hold
27
– – ﹤0.01% 1221
2024
Q3
$500 Sell
27
-37
-58% -$743 ﹤0.01% 1162
2024
Q2
$1.3K Buy
+64
New +$1.13K ﹤0.01% 853

Other funds holding CLB

Fortitude Family Office's CLB Position: Q2 2026 in Review

Fortitude Family Office increased its Core Laboratories (CLB) stake by 22% in Q2 2026, buying an estimated $899 and bringing the position to 348 shares worth $4.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1182.

Fortitude Family Office first reported a position in CLB in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.79K in Q1 2026. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • Fortitude Family Office held 348 shares of Core Laboratories worth $4.05K as of Q2 2026.
  • Fortitude Family Office bought 63 Core Laboratories shares in Q2 2026, an estimated $899.
  • Core Laboratories made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1182 holding.
  • Fortitude Family Office first reported a position in Core Laboratories in Q2 2024 and has held it in 9 quarters since.
  • Fortitude Family Office's Core Laboratories position peaked at $4.79K in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.